Projects per year
Kate is a medical oncologist with a keen interest in breast and gynaecological oncology, cancer survivorship and clinical trials. Kate graduated from the University of New South Wales in 2002 with first class honours and completed her specialty training in medical oncology at St George and Prince of Wales Hospitals in Sydney. She was then appointed the inaugural Survivorship Research Fellow at the National Centre for Cancer Survivorship at the University of New South Wales where she completed a PhD examining long term health and psychosocial issues affecting cancer survivors whilst looking at novel models of care for these patients. Research arising from her PhD has been presented at scientific meetings for the American Society of Clinical Oncology, International Gynaecological Cancer Society and European Society of Gynaecological Oncology, in addition to Australian meetings. Prior to her appointment at Monash Health, Kate held staff specialist appointments in medical oncology at Prince of Wales Hospital and the Royal Hospital for Women in Sydney, as well as an honorary appointment at Sydney Children’s Hospital. At Prince of Wales Hospital she also served as Clinical Superintendent for Medicine and co-Director of Advanced Physician Training, as well as convenor of the UNSW Human Research Ethics Advisory Panel (Biomedical). Kate is the current co-chair of the Cancer Institute NSW eviQ Medical Oncology Reference Committee and formerly served as a member on its in gynaecological cancer and sarcoma committees.
PhD, University of New South Wales
Award Date: 21 Sep 2016
FRACP, Royal Australasian College of Physicians
Award Date: 8 Dec 2010
B.Sc(Med) MBBS (honours class 1), University of New South Wales
Award Date: 13 Dec 2002
eviQ Medical Oncology Co-chair, Cancer Institute NSW30 Aug 2019 → …
Medical oncologist, Monash Health3 Dec 2018 → …
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
15/11/19 → 14/11/24
PRECISE: A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion
20/09/19 → 19/09/24
Research Output per year
OVQUEST – Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivorsWebber, K., Carolus, E., Mileshkin, L., Sommeijer, D., McAlpine, J., Bladgen, S., Coleman, R. L., Herzog, T. J., Sehouli, J., Nasser, S., Inci, G. & Friedlander, M., Oct 2019, In : Gynecologic Oncology. 155, 1, p. 126-134 9 p.
Research output: Contribution to journal › Article › Research › peer-review
Research output: Contribution to journal › Review Article › Research › peer-review
Cardiovascular toxicity of targeted therapies for cancer: A protocol for an overview of systematic reviewsVan Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S. A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, 7 p., e021064.
Research output: Contribution to journal › Review Article › Other › peer-review